Frailty and benign prostatic hyperplasia: The thrilling underlying impact.

BACKGROUND: World population is aging. The number of individuals aged over 65 are expected to be 71 million only in the US. 43% of this population will be men. Benign prostatic hyperplasia (BPH), defined as the benign neoplasm of the prostate gland affects 8% of men by their forties, but 90% of men over 90 years old. Lower urinary tract symptoms (LUTS) can be caused by an enlarged prostate, and it seems to be associated more with older and frailer individuals. METHODS: The purpose of this study is to review the potential interplay between frailty syndrome and benign prostatic hyperplasia. A thorough MEDLINE/PubMed non-systematic literature review was conducted from 1990 to March of 2022. The terms used for the search were "frailty and benign prostatic hyperplasia" and "low muscle mass and benign prostatic hyperplasia". RESULTS: It seems that, frailty poses a negative impact on the prognosis of patients with BPH, as it is associated with increased incidence of LUTS. In addition, frailty seems to be a strong predictor concerning surgical procedure failure and mortality following invasive procedures for BPH. Prostatic stent placement on the other hand appears to be the ideal solution for frail patients. CONCLUSIONS: BPH has a strong association with frailty and increasing age.

Sarcopenia in Urinary Bladder Cancer: Definition, Prevalence and Prognostic Value in Survival.

Sarcopenia, defined as the systemic loss of muscle function and mass, is commonly seen in advanced oncologic states, usually in conjunction with cancer cachexia. Bladder cancer represents one of the most common neoplasms worldwide and affects mainly the elderly who are already frail. The purpose of this study is to review the potential association between sarcopenia and bladder cancer in patients receiving different types of treatments. A thorough MEDLINE/PubMed non-systematic literature review was conducted from 1990 to January 2022, using the following search terms: "sarcopenia and bladder cancer" and "low muscle mass and bladder cancer". Sarcopenia probably poses a negative impact on the prognosis of patients at any stage of bladder cancer, as it is linked with overall worse survival, cancer specific survival and progression-free survival in those treated, with either radical cystectomy or chemotherapy. In addition, sarcopenia seems to be a strong predictor concerning complications and a negative prognostic factor following chemotherapy and surgery for bladder cancer. On the other hand, it seems that sarcopenic patients who receive radiotherapy or immunotherapy are not so severely affected.

Insight in schizophrenia and mood disorders and its relation to psychopathology.

The authors assessed insight on admission on the 15th, 30th and discharge day in 77 female inpatients (42 schizophrenic, 13 manic, 22 depressives) using McEvoy's Insight and Treatment Attitude Questionnaire (ITAQ) and studied its relation to psychopathology, which was assessed by completion of the Brief Psychiatric Rating Scale (18-item version). The data suggest that depressives had good initial (on admission) insight, schizophrenics the poorest, followed shortly by manics. Insight (ITAQ total score) improved significantly after treatment in both mania and schizophrenia. Moreover a constantly significant negative correlation existed between ITAQ and BPRS in mania but not in schizophrenia, indicating that other factors besides psychopathology might influence insight in schizophrenia.